Respiratory Syncytial Viral Infections Among Hospitalized Youth With Sickle Cell Disease
- 22 October 2026
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- p. e70780
Abstract
Respiratory syncytial virus (RSV) imposes substantial risk to all infants, but its impact on youth with SCD (Y‐SCD) is underexplored. With newer, highly effective RSV monoclonal antibodies (RSV‐mAb), research is needed to inform their use in Y‐SCD. This single‐center study of Y‐SCD aged 0–21 years identified 667 hospitalizations that included RSV testing. Of these, 5% were positive for RSV, and 68% occurred in Y‐SCD beyond their first RSV season. Intensive care, positive pressure ventilation, and transfusion were required in 21%, 32%, and 21% of hospitalizations, respectively. Findings indicate that multicenter studies are warranted to determine if RSV‐mAbs improve outcomes in Y‐SCD.Keywords
This publication has 7 references indexed in Scilit:
- Clesrovimab in Infants and Children at Increased Risk for Severe RSV DiseaseNew England Journal of Medicine, 2025
- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025MMWR. Morbidity and Mortality Weekly Report, 2025
- Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised HostsPediatric Blood & Cancer, 2024
- Seasonality of Respiratory Syncytial Virus — United States, 2017–2023MMWR. Morbidity and Mortality Weekly Report, 2023
- Influenza vaccination rates and hospitalizations among Medicaid enrollees with and without sickle cell disease, 2009–2015Pediatric Blood & Cancer, 2021
- The burden of respiratory syncytial virus infections among children with sickle cell diseasePediatric Blood & Cancer, 2020
- Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell diseasePediatric Blood & Cancer, 2014